Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Chimeric Receptor T Cells + Trastuzumab in HER2+ Advanced Solid Tumors
NCT06027983Phase 2Not yet recruiting
- Sponsor
- National University Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2026
01
Overview
Phase 2, open-label, single-arm trial in breast cancer, gastric cancer (GC) and solid tumor, sponsored by National University Hospital. Primary endpoints: Time to treatment failure at 3 years, Progression-free survival at 3 years and 3 more. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
breast cancergastric cancer (GC)solid tumor
Beyond the preview
Go deeper on NCT06027983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027983.